SCHEMBL810867

SCHEMBL810867

Cc1ccc2c(Nc3cccc(OCc4cc(F)cc(F)c4)c3)ncnc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.48
PIM1 P11309 1/20 0.43
AKT2 P31751 1/20 0.43
KDR P35968 3/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
EPHA2 P29317 1/20 0.43
EPHB4 P54760 1/20 0.43
DYRK3 O43781 1/20 0.42
MAP4K4 O95819 1/20 0.42
PDGFRA P16234 1/20 0.42
LTK P29376 1/20 0.42
GRK5 P34947 1/20 0.42
MAPK8 P45983 1/20 0.42
CDK8 P49336 1/20 0.42
CDK7 P50613 1/20 0.42
IRAK1 P51617 1/20 0.42
NEK4 P51957 1/20 0.42
LIMK1 P53667 1/20 0.42
ACVR1 Q04771 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810419 0.94 EGFR (0.48) EGFRERBB2FBP1GAK
SCHEMBL810369 0.87 EGFR (0.46) EGFRKDRRAB9ANPC1EPHA2
SCHEMBL810919 0.84 EGFR (0.43) EGFRPIM1AKT2KDRRAB9A
SCHEMBL810280 0.84 EGFR (0.57) EGFRKDRRAB9ANPC1EPHA2
SCHEMBL810367 0.84 EGFR (0.57) EGFRPIM1AKT2FBP1
SCHEMBL810793 0.81 EGFR (0.46) EGFRRAB9AHTTERBB2FBP1
SCHEMBL810666 0.78 EGFR (0.55) EGFRRAB9AABCG2HTTERBB2
SCHEMBL810989 0.78 EGFR (0.57) EGFRKDRRAB9ANPC1DYRK3
SCHEMBL810328 0.76 EGFR (0.46) EGFRKDRRAB9ANPC1DYRK3
SCHEMBL811077 0.75 EGFR (0.73) EGFRAURKBABCG2ERBB2FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 EGFR 2701/4885PIM1 2963/4885AKT2 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.